Apogenix has developed a proprietary HERA-ligand technology platform that focuses on creating novel receptor agonists targeting the tumor necrosis factor superfamily (TNFSF) signaling pathways. This platform utilizes single-chain TNFSF (scTNFSF) constructs, which are designed to enhance receptor clustering and signaling efficacy compared to traditional agonistic antibodies. The HERA-ligands are hexavalent compounds that facilitate well-defined receptor clustering, allowing for a more effective transmission of signals into target cells. This technology is currently being applied in the preclinical development of various agonists, including those targeting CD40, GITR, and 4-1BB, with the potential for broad applications in oncology.

The HERA-ligand platform's design is based on the natural structure of TNFSF proteins, which typically exist as homo-trimers. Apogenix's approach involves constructing a single polypeptide chain that mimics the receptor-binding domain (RBD) of these proteins, allowing for enhanced signaling without the need for secondary cross-linking. This innovative design leads to multiple protein formats that can be tailored for specific therapeutic purposes, including trivalent and hexavalent constructs with varying pharmacokinetic properties. The versatility of the HERA-ligand technology positions Apogenix to develop a range of anti-cancer biologics that can effectively modulate immune responses against tumors.

Germany

Apogenix develops innovative immunotherapeutics for the treatment of cancer and viral infections, such as COVID-19. The company has built a promising pipeline of drug candidates that target different TNFSF-dependent signaling pathways, thereby reducing lymphopenia and inflammatory cell death in patients with viral infections and restoring the anti-tumor immune response in cancer patients.

Apogenix

Company Details